NCT06216054已完成1 期
A Randomized, Double-blind, Placebo-controlled, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 Sustained-release Tablets in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Treatment-emergent adverse event
研究概览
简要总结
This is a single-center, randomized, double-blind, placebo-controlled, multiple-ascending doses trial to evaluate the safety, tolerability and pharmacokinetic of LPM3770164 sustained-release tablets orally administered in healthy subjects under fasting state, providing the rationale information for later clinical trials.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject who voluntarily participate and sign the informed consent form;
- •Healthy male/female volunteers aged 18 to 45 years;
- •Body weight ≥ 50.0 kg for men and ≥ 45.0 kg for women, and body mass index (BMI) 18.5 ~ 26.0 kg/m2, inclusive;
- •Able to comply with the lifestyle restrictions.
排除标准
- •Subject has a history of allergy to any component of the investigational drug or similar drugs, or allergic constitution;
- •Subject has a current or past medical history that may affect the clinical trial or dysfunction, including but not limited to the past or current respiratory system, circulatory system, digestive system, urinary system, reproductive system, nervous system, endocrine system, immune system, motor system, blood system, psychiatry/ psychology, dermatology and other clinically serious diseases or chronic diseases; or any other diseases that may interfere with the test results;
- •Any surgical condition or condition may significantly affect the absorption, distribution, metabolism and excretion of the drug, or may pose a hazard to the subjects;.
- •Subject has a history of self-mutilation; or at risk of suicide;
- •Subject has a history of surgery within 3 months prior to administration, or failure to recover from surgery, or having an expected surgical plan during the trial;
- •Subject has abnormal vital signs, laboratory abnormalities, and ECGs;
- •Subject has used any of over-the-counter products within 7 days or prescription medications within 28 days prior to dosing;
- •Subject positive for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), HIV antibody (HIV-Ab), or syphilis seroreactivity (Trust);
- •Subject has a history of alcohol abuse within 1 year or positive alcohol breath test results;
- •Subject has a history of substance abuse within 1 year or a positive urine drug screen;
- •Subject who has daily smoking of ≥ 5 cigarettes within 3 months;
- •Subject who has special requirements for food, cannot comply with the unified diet or have dysphagia;
- •Subject who has consumption of xanthine-rich foods or beverages (such as tea, coffee, cola, or chocolate) within 3 days prior to administration;
- •Subject who has consumption of food or beverages containing grapefruit within 7 days prior to administration;
- •Subject who has participated in other clinical trials within 3 months before administration;
- •Subject has used blood products or being blood donor or blood loss within 3 months;
- •Pregnant, lactating women, or positive pregnancy test;
- •Subject who refusal to contraception, or plan to donate sperm or ovums;
- •Other conditions which would make participation in the study unsuitable.
研究组 & 干预措施
LPM3770164
Experimental
LPM3770164 sustained-release tablets will be administrated with multiple doses from 5mg to 30mg on day 1~10
干预措施: LPM3770164 sustained release tablet (Drug)
Placebo
Placebo Comparator
LPM3770164 sustained release tablet simulant will be administrated on day 1~10
干预措施: LPM3770164 sustained release tablet simulant (Drug)
结局指标
主要结局
Treatment-emergent adverse event
时间窗: from baseline to day 37
Number of participants with treatment-emergent adverse event will be summarized by Group, System Organ Classification (SOC), Preferred Term (PT), severity and the relationship with treatment.
次要结局
- Area Under the Curve from time 0 to 24 hours (AUC0-24)(from day 1 to day 24)
- ECG QTc Interval(from baseline to day 37)
- Peak Plasma Concentration (Cmax)(from day 1 to day 24)
- Area Under the Curve from time 0 to the last measurable concentration (AUC0-t)(from day 1 to day 24)
- Half-life (t1/2)(from day 1 to day 24)
- Area Under the Curve from time 0 extrapolated to infinity (AUC0-inf)(from day 1 to day 24)
- Time to maximum concentration (Tmax)(from day 1 to day 24)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy SubjectsDrug SafetyNCT01519531Madrigal Pharmaceuticals, Inc.48
已完成
1 期
Multiple Dose Study of Safety and Pharmacokinetics of MEDI0618 in Healthy VolunteersChronic PainNCT05714254AstraZeneca36
已完成
1 期
A Phase 1 Safety and PK Study of IV TP-271Bacterial InfectionsNCT03234738Tetraphase Pharmaceuticals, Inc.40
已完成
1 期
Multiple Ascending Doses of ZP4207 Administered to HV to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207HypoglycemiaNCT02390141Zealand Pharma24
已完成
1 期
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT02391259Amgen57